Based on the level of PD-1 expression on CD4+ T cells, we defined high-PD-1 (PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) subgroups in NSCLC patients. The gene discussed is CD4; the disease is non-small cell lung carcinoma.